Celgene Corporation, a top 50 pharma company has entered into strategic pharma alliances agreement with PharmAria to advance the discovery of new high quality small-molecule therapeutics targeting cancer and fibrotic diseases.
In terms of this pharma alliances deal, Celgene will provide seed-stage funding for PharmAria, and will work with PharmAria to secure additional Series A venture funding in which Celgene will also participate.
Following a successful Series A financing, Celgene will receive an equity position in PharmAria, as well as the option to license certain research and development programs.
The strategic pharma alliances pact may also see , Celgene acquiring PharmAria at a later date.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigpharma Partnering Yearbook 2013
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity